Accéder au contenu
Merck

Replacing GnRH agonists with GnRH antagonists in oocyte recipient cycle did not adversely affect the pregnancy rates.

European journal of obstetrics, gynecology, and reproductive biology (2011-07-06)
Francisca Martínez, Laura Latre, Elisabet Clua, Ignacio Rodriguez, Buenaventura Coroleu
RÉSUMÉ

The synchronization of the donor stimulation with the endometrial preparation of the recipient is usually done by downregulating the recipient's pituitary with a GnRH analog. The aim of this study is to compare pregnancy and implantation rates among premenopausal oocyte recipients synchronized by pituitary suppression with GnRH agonist (Group AGO) or antagonist (Group ANTAG) and standard endometrial preparation with estrogen and gestagen. Prospective, observational, transversal, comparative study. Consecutive recipients treated at Institut Universitari Dexeus between July 2008 and December 2009. One hundred and eighty-three premenopausal women were included. No differences were found regarding the age of donors nor the age of recipients, fertilization rates, number of embryos transferred and embryo quality. No differences were found in clinical pregnancy rates (56.1% Group AGO vs. 52.4% Group ANTAG). The administration of GnRH antagonists during endometrial preparation in oocyte recipients facilitates synchronization without affecting the pregnancy rate.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ganirelix acetate salt, ≥95% (HPLC)